Swisscanto and imec.xpand led a CHF12.4m Series A round in Nagi Bioscience, a Swiss life sciences company developing next-generation laboratory equipment to unlock the alternatives to animal testing, with participation from Excellis, Verve Ventures, and Zürcher Kantonalbank. “The enthusiastic support from our new investors reflects our belief in Nagi’s potential to disrupt the drug discovery and toxicology testing markets. We are deeply grateful for their trust in our vision. This substantial investment is a testimony of the hard work, dedication, and passion of our incredible team and will be instrumental now in scaling-up the commercial organization and operations, while expanding R&D activities to strengthen Nagi’s portfolio of innovative products,” Matteo Cornaglia, Nagi Bioscience, CEO and Co-Founder.